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disease have been predominantly M types 1 and 3, 
which may produce pyrogenic exotoxin A or B or both 
[2-41. We have isolated an M-type 12 GAS strain that 
possesses pyrogenic exotoxin genes for A, B and C from 
a patient with toxic shock syndrome (TSS). 
A 73-year-old male patient was admitted to 
hospital for angioplasty treatment. On the first day 
following surgery he became febrile ( d a r y  tempera- 
ture 39.7"C), with prostration and tachypnea. During 
the next 2 days his blood pressure fell from 119/60 to 
65/33 and he presented with leukopenia (3.2 x 109/L), 
neutrophilia (95%), thrombocytopenia (76 x 109/L), a 
low fibrinogen level (267 mg%), prolonged clotting 
times (PT 78%=1.3 INR, APTT 42 s), the presence 
of fibrinogen degradation products (> 20 mg/L), liver 
involvement (alanine aminotransferase 105 U/L), 
rapidly progressive renal failure (creatinine values of 
203.3-415.5 pmol/L), uncompensated metabolic acid- 
osis and mental confusion. He developed cardiac shock 
(systolic blood pressure $40 mmHg) and multi-organ 
failure. He died of cardiorespiratory arrest on the 
morning of the fourth day, despite supportive therapy. 
Blood cultures (Hkmoline performance diphasique, 
bioMCrieux, France) performed on the first day were 
positive on day 3 and yielded Lancefield group A 
streptococci as identified by fi-hemolysis on blood 
agar and latex agglutination (Slidex Strepto-Kit, 
bioMkrieux, France). Further studies undertaken at the 
PHLS Streptococcus and Diphtheria Reference Unit 
(London) identified the GAS as M-type 12 with the 
presence of three exotoxin genes, A, B and C [l]. 
A definitive portal of entry could not be ascertained 
because the patient died before further specimens from 
the upper respiratory tract or skin lesions could be 
collected. It is likely that the streptococcal infection 
resulted from trauma during surgery, as skin lesions are 
generally the most commonly reported predisposing 
factor for invasive disease [1,3,5]. All staff members 
who were in contact with the patient were questioned 
about the presence of possible streptococcal infection, 
and swabs were taken from their throats and any skin 
lesions. GAS strains were not isolated from the staff. 
The possession of all three genes is not usual in 
M12 strains but this has been documented [1,6]. To our 
knowledge, this is the first time that an M12 strain with 
all three pyrogenic exotoxins has been identified in 
Portugal. 
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The fi-clnemokine receptor 5 (CCR-5) is the major 
co-receptor for macrophage-tropic non-syncytium- 
inducing isolates of HIV-1 [l]. These strains pre- 
dominate during the asymptomatic phase of the disease 
in infected individuals and are implicated in about 90% 
of cases of sexual transmission of HIV-1 [ 2 ] .  Some 
subjects who remain uninfected despite extensive 
high-risk sexual exposure to HIV-1 have been recently 
shown to have an identical homozygous defect con- 
sisting of a 32-nucleotide deletion in the CCR-5 
gene (A32) [3-61. Both epidemiologic data and in 
vitro studies support the firm conclusion that A32 
homozygotes are highly resistant to sexual acquisition 
of infection because their cells fail to express the 
functional co-receptor for macrophage-tropic strains 
of HIV-1 [3-61. Peripheral blood mononuclear cells 
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(PBMCs) from A32 heterozygous subjects have shown 
a 4-10-fold reduction in the ability to replicate HIV-1 
in vitro in some [5,7] but not all [8] studies. While 
Samson et a1 [5] reported a higher prevalence of A32 
heterozygosity in seronegative than in seropositive 
individuals, suggesting partial protection with one 
CCR-5 A32 allele, other epidemiologic studies have 
shown similar frequencies of A32 heterozygosity in 
different cohorts of HIV-1 -infected and uninfected 
homosexual men [4,6,9]. However, several reports 
indicate that A32 heterozygosity may confer some 
degree ofprotection against disease progression in HIV- 
1-infected patients, being associated with prolonged 
AIDS-free survival and low viral load [4-6,9-121. 
Thus, the role of heterozygosity in HIV-1 transmission 
and disease progression merits further investigation. 
We analyzed PBMC samples from 135 subjects 
from central Italy for the presence of the A32 defect 
in the CCR-5 gene by using the polymerase chain 
reaction [5]. The population analyzed included the 
following groups: 19 HIV-1-infected and 46 uninfected 
heterosexual individuals, 36 HIV-1-infected and seven 
uninfected homosexual men, 12 HIV-1-infected rapid 
progressors (RPs), and 15 HIV-1 -infected long-term 
non-progressors (LTNPs). All of the uninfected hetero- 
sexual subjects had been regular sexual partners of 
an infected subject for > 5 years. RPs were defined by 
AIDS diagnosis within 4 years after seroconversion. 
LTNPs were defined by >12 years of asymptomatic 
infection with CD4 counts always >500/mm3 in the 
absence of any antiretroviral therapy. We did not find 
any individual homozygous for CCR-5 A32 in the six 
groups examined. Data for A32 heterozygosity are 
shown in Table 1. There was no significant difference 
in the prevalence of the CCR-5 A32 allele between 
the HIV-1 infected and uninfected sexually exposed 
groups. These findings are in agreement with 
epidemiologic data obtained with homosexual men 
[4,6] and additionally indicate that A32 heterozygosity 
confers limited, if any, protection against heterosexual 
acquisition of HIV-1 infection. Also, the prevalence of 
Table 1 Heterozygosity for the CCR-5 A32 deletion in 
the groups examined 
~ ~~ ~ 
No. heterozyyous/no. tested (“Yo) 
Group HIV-1 infected Uninfected 
Homosexual men 5/36 (13.9%) 1/7 (14.3%) 
Heterosexual subjects 1/19 (5.3%) 9/46 (19.6%) 
Total 6/55 (10.9%) 10/53 (18.9%) 
Rapid progressor? 2/12 (16.7%) 
Long-term non-progressors 3/15 (20.0%) 
the A32 defect was not significantly different between 
RPs and LTNPs. It must be noted that these statistical 
evaluations are based on small numbers of subjects. 
However, when HIV-1 R N A  load data obtained for 
LTNP subjects at 10 years since seroconversion were 
examined, the median value of the A32 heterozygous 
LTNPs was significantly lower than that of the wild- 
type CCR-5 homozygous LTNPs (1000 and 41 490 
copies/mL, respectively; p=0.025). This indicates that 
A32 heterozygosity may help to maintain the LTNP 
state, as predicted by a long-lasting low-level HIV-1 
viremia. Although a role for the A32 heterozygous 
defect in slowing disease progression is being con- 
sistently suggested [6,9-121, further studies are advis- 
able to better define such a role. In particular, well- 
standardized criteria for rating disease progression 
should be used in order to avoid possible biasing of 
results. Based on presently available data, it seems 
reasonable that a reduced expression of a functional 
CCR-5 co-receptor in A32 heterozygotes does not 
efficiently prevent acquisition of infection but possibly 
alters the course of HIV-1 infection, depending on a 
number of additional virus and host factors. 
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Rhodococcus equi systemic infection in an HIV-infected 
child 
Clin Microbiol Infect 1998; 4: 353-354 
Rhodococcus equi is a well-known pathogen in veterinary 
medicine. It is also a rare but emerging opportunistic 
pathogen in immunocompromised patients. Since the 
first description ofa human infection in 1967 [l], about 
50 cases have been reported. The incidence of human 
R. equi infection is increasing, largely owing to the 
human immunodeficiency virus (HIV) pandemic [2-51. 
We present a case of R. equi bacteremia in an HIV-1- 
infected child, in whom the opportunistic infection 
revealed HIV-1 infection. 
A 5-year-old girl was referred to St Mary Pediatric 
Hospital in Iasi, Romania, with fatigue, loss of appetite, 
weight loss, dry cough and fever (38-4OOC) in August 
1994. The fever had started 3 weeks previously and 
persisted despite ambulatory treatment with penicillin 
and ampicillin. 
O n  examination she had micropolyadenopathy 
with painless, mobile, asymmetric nodes, tonsillar 
hypertrophy and hepatomegaly. Fine crackles were 
heard on both sides of her chest. She had tachycardia 
(120 beatslmin) and a systolic murmur in all the 
auscultation points. The peripheral white blood cell 
count was 11.4x109/L, with 74% neutrophils. No 
evidence of pneumonia was observed on the chest 
radiograph. 
A Gram-positive coccobacillus was isolated from 
two of three blood samples, after 4 and 7 days in 
culture. The colonies were small, irregular, round, 
smooth, :semi-transparent, mucoid and salmon-pink. 
The bacterium was pleomorphic, ranging from 
distinctly coccoid to rod-shaped. It was an obligate 
aerobe, catalase positive, oxidase negative and urease 
positive. R. equi infection was confirmed by full 
identification at the Pasteur Institute in Paris @r  M. 
Kiredjian). 
The disk diffusion method showed that the two 
isolates were sensitive to penicillin, ampicillin, ceftria- 
xone (MIC 0.03 mg/L), cehzidime (MIC 0.05 mg/L), 
cefotaxime (MIC 0.03 mg/L), erythromycin, genta- 
micin and co-trimoxazole, intermediately susceptible 
to rifampicin, and resistant to tetracycline. 
SpeciFic parented therapy was started with ceftria- 
xone, and gentamicin was added 4 days later. A clinical 
and biological response was observed after 24 h, fever 
started to abate on day 2 and ceased on day 5, and the 
C reactive protein level was normal by day 7. This 
treatment 'was maintained for 2 weeks and was followed 
by ampicillin therapy for 35 days. As R. equi infection 
occurs mainly in immunocompromised hosts, the 
patient was tested for HIV-1 infection; serotyping by 
subtype-specific enzyme immunoassay (SSEIA) showed 
she was infected by HIV-1 subtype F [6]. Flow cyto- 
metry showed a CD4/CD8 cell ratio of 0.65 (CD4 cell 
count: 380 x 106/L). She made a full recovery and did 
not relapse on treatment withdrawal. 
This case has several interesting features: 
(1) To our knowledge this is the first description of 
R. equ,i infection in an HIV-I-infected child. She 
had had no known contact with animals and no 
specific site of infection; in particular, there was 
no clinical or radiologic evidence of pulmonary 
involvement, in contrast to the majority of reported 
cases [I-3,5,7]. 
(2) R. equi infection was diagnosed prior to the 
discovery of HIV-1 infection, and was the first 
clinical manifestation of HIV- 1 disease. 
(3) The response to antibiotic therapy was favorable, 
after a short course (2 weeks) of cehiaxone and 
gentamicin, followed by 35 days of ampicillin. This 
confirms a previous report showing the efficacy of 
ceftriaxone in the treatment ofR. equi infection [7]. 
In contrast, there have been several reports of 
treatment failure in immunocompromised patients 
